Eli Lilly and Purdue University, US, have announced the widening of their existing partnership with a planned investment of ...

Each week high schools are invited to nominate an outstanding student for the honor. Meet these highly accomplished students.

People taking Eli Lilly and Co.'s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's ...

In a way, the requiem of a now dismantled agency that promoted U.S. security through development and humanitarian work abroad ...

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...

The first reveal of clinical data with Eli Lilly’s injectable triple receptor agonist for obesity suggests that the company could have a big winner on its hands if the drug makes it through to ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.